AI Insight
Researchers tested whether Reelin protein, which is reduced in depression, could reverse chronic stress-induced behavioral changes in rats without causing brain inflammation. Using male rats given corticosterone to simulate chronic stress, they found that Reelin injections (either a single 3 μg dose after stress or three doses during stress) rapidly reversed despair-like behaviors without triggering pro-inflammatory changes in microglia, the brain's immune cells. This suggests Reelin could be developed as a rapid-acting antidepressant without the adverse effect of neuroinflammation.
Why it matters
Current antidepressants often take weeks to work and have limited efficacy. If Reelin's effects translate to humans, it could represent a new class of fast-acting antidepressants that address stress-related depression without exacerbating brain inflammation, a concern given that high Reelin levels may otherwise promote inflammatory responses.
Understand the Science
⚠️ Preprint – Noch nicht peer-reviewed
Dieser Artikel wurde noch nicht von unabhängigen Experten begutachtet. Die Ergebnisse sind vorläufig und sollten mit Vorsicht interpretiert werden.
Chronic stress elicits widespread, multisystem alterations, among them the increased production of inflammatory mediators by immune cells, that culminate in physiological and psychological disruptions. Microglia are resident macrophages of the CNS that show altered morphology alongside increases in pro-inflammatory cytokine release and phagocytosis in response to chronic stress. Chronic stress-induced behavioural and physiological alterations can be replicated in rats using daily injections of corticosterone (CORT) over a prolonged period. Reelin, a glycoprotein reduced in depression and animal models of chronic stress, rapidly reverses chronic CORT-induced symptoms following a single 3 g injection. However, high levels of reelin may be pro-inflammatory, indicating the need to determine if a dose of reelin that resolves chronic stress-induced impairments exacerbates neuroinflammation as a possible adverse effect of reelin treatment. Using either a single 3 g reelin injection following chronic stress or repeated (3) reelin injections throughout chronic stress in male Long Evans rats, we show that reelin does not promote microglia morphologies indicative of pro-inflammatory function within the context of chronic stress, and that both reelin administration schedules rapidly reverse chronic stress-induced despair-like behaviour. These results offer insight into the effect of peripheral reelin administration on processes underlying neuroinflammation and suggest that restoring reelin following chronic stress does not exacerbate microglia-driven neuroinflammation. This research together with past research from our lab supports the advancement of reelin or reelin peptides towards clinical evaluation as a rapid antidepressant.